HomeAI · summaries
Storia in 8 fonti
Mapp, Gilead antivirals to be deployed in DRC Ebola trial: WHO chief
As health officials grapple with a fast-moving outbreak of the Bundibugyo ebolavirus in the Democratic Republic | Officials are planning to study Mapp Biopharmaceutical’s MBP134 and Gilead Sciences’ remdesivir, which gained prominence during the COVID-19 pandemic, against the Bundibugyo ebolavirus.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
thecitizen.co.tz
US provides Ebola treatment for outbreak in Congo, bringing trials closer
Phase 1 trials could begin in July, likely in the UK and possibly Uganda, Richard Hatchett, chief executive of the Coalition for Epidemic Preparedness Innovations, said in an…
- ·
dailysabah.com
US sends experimental Ebola drug to DRC as outbreak trials expand
The United States is stepping into a more direct role in the Ebola response in the Democratic Republic of Congo by supplying doses of an experimental...
- ·
rfi.fr
US releases experimental Ebola drug for DR Congo outbreak trials
Experimental Ebola drugs are being shipped to Democratic Republic of Congo as the United States releases doses of a treatment for clinical trials in a widening outbreak that has…
- ·
statnews.com
Clinical trial set to test two drugs for fast-growing Ebola outbreak
A clinical trial testing two drugs against the Bundibugyo ebolavirus, which is driving a fast-moving outbreak in Central Africa, is set to begin next week, WHO officials said.
- ·
nbcnews.com
U.S. provides experimental Ebola treatment for outbreak in Congo, bringing trials closer
The U.S. had previously said that the antibody drug from Mapp Biopharmaceutical would only be made available to Americans deemed to be at high risk after exposure to the virus.
- ·
vanguardngr.com
Trials of two Ebola treatments to start in DRC next week - WHO
Trials of two separate potential treatments to fight the deadly Ebola outbreak in the Democratic Republic of Congo are expected to begin next week, the World Health Organisation…
- ·
fiercebiotech.com
Mapp, Gilead antivirals to be deployed in DRC Ebola trial: WHO chief
As health officials grapple with a fast-moving outbreak of the Bundibugyo ebolavirus in the Democratic Republic | Officials are planning to study Mapp Biopharmaceutical’s MBP134…
- ·
africanews.com
World Health Organization announces trial of two potential Ebola treatments | Africanews
They will begin next week in the DR Congo to see whether two antivirals can help reduce mortality in patients with the rare Bundibugyo strain of the virus.